To unravel the effects of the novel inhaled PDE4 inhibitor tanimilast on neutrophil effector functions with the view of its usage in COPD, neutrophils were challenged with bacterial or viral-mimetic agonists. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.